AGLE News and Press, Aeglea BioTherapeutics Inc. From 08/18/22

Aeglea BioTherapeutics ( NASDAQ: AGLE ) on Thursday said Europe's drug regulator had validated the company's marketing authorization application for enzyme pegzilarginase for the treatment of Arginase 1 deficiency. Shares of the micro-cap clinical-stage biotech soared 57.5% ...

Aeglea BioTherapeutics Announces European Medicines Agency Validation of Marketing Authorization Application for Pegzilarginase for the Treatment of Arginase 1 Deficiency PR Newswire AUSTIN, Texas , Aug. 18, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, In...

Aeglea BioTherapeutics press release ( NASDAQ: AGLE ): Q2 GAAP EPS of -$0.27 (vs. -0.10 Y/Y) beats by $0.04 . Revenue of $0.63M (-95.4% Y/Y) misses by $0.08M . Shares +5.07% PM. For further details see: Aeglea BioTherapeutics GAAP EPS of -$0.27 be...

Aeglea BioTherapeutics Reports Second Quarter 2022 Financial Results and Provides Program Updates PR Newswire Cohort 2 Completed in Phase 1/2 Trial of AGLE-177; Data Expected in Fourth Quarter of 2022 Actively Engaged with FDA to Identify Potential Paths Forwar...

Baker Brothers’ 13F portfolio value decreased from $20.55B to $17.40B this quarter. Horizon Therapeutics was increased while decreasing Legend Biotech. The top three positions are Seagen, Incyte Corporation, and BeiGene, and they add up to almost 68% of the portfolio. ...

Gainers: Immix Biopharma (IMMX) +37%. Bright Green (BGXX) +29%. Repare Therapeutics (RPTX) +29%. Yumanity Therapeutics (YMTX) +24%. PDS Biotechnology (PDSB) +15%. Losers: Zosano Pharma (ZSAN) -48%. Immunic (IMUX) -41%. Aeglea BioTherapeutics (AGLE) -40%...

The U.S. FDA has issued Aeglea BioTherapeutics (NASDAQ:AGLE) a Refuse to File letter for pegzilarginase for Arginase 1 Deficiency. The letter asks for more data to demonstrate efficacy as well as additional information related to chemistry manufacturing and controls. No safety concerns w...

Aeglea BioTherapeutics Receives Refusal to File Letter from FDA for Pegzilarginase for the Treatment of Arginase 1 Deficiency PR Newswire AUSTIN, Texas , June 2, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnol...

Piper Sandler cut its price target (PT) on 17 companies in the biotech space reflecting the recent pullback in the stock and prevailing market conditions. Piper Sandler also noted that biotech valuations have re-rated. Following are the stocks which saw their PT lowered: Gene editing com...

Aeglea BioTherapeutics (NASDAQ:AGLE) entered into a securities purchase agreement with certain institutional investors providing for the purchase and sale of registered securities in a registered direct offering for gross proceeds of ~$45M. The financing includes 10.75M shares at $1.6/sh...